Cartesian Therapeutics, Inc. (RNAC) Free cash flow 2016–2025
Cartesian Therapeutics, Inc. (RNAC) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$79.4MFY2025 · since FY2016: -$20.3M → -$79.4M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$79.4M | -142.3% |
| FY2024 | -$32.8M | +36.2% |
| FY2023 | -$51.4M | -56.5% |
| FY2022 | -$32.8M | +46.6% |
| FY2021 | -$61.5M | -280.4% |
| FY2020 | $34.1M | +166.2% |
| FY2019 | -$51.5M | +14.3% |
| FY2018 | -$60.0M | -13.8% |
| FY2017 | -$52.8M | -159.3% |
| FY2016 | -$20.3M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More RNAC financial trends
RNAC RevenueRNAC Net incomeRNAC Net marginRNAC Gross profitRNAC Gross marginRNAC Operating incomeRNAC Operating marginRNAC Operating cash flowRNAC Capital expendituresRNAC Return on equityRNAC Stock buybacksRNAC Dividends paidRNAC Total assetsRNAC Total liabilitiesRNAC Shareholders’ equityRNAC overview →